The use of gadolinium based MRI contrast agents has been directly linked to the development of nephrogenic systemic fibrosis (NSF) among individuals with kidney problems. Although it is known that gadolinium contrast causes the painful and debilitating condition, researchers have been unsure of exactly why. A new study provides a possible explanation and could lead to a strategy for preventing and treating NSF.

Nephrogenic systemic fibrosis (NSF), previously known as Nephrogenic Fibrosing Dermopathy (NFD), is a rare disease which is associated with the development of hard and thick skin, which severely restricts movement of the joints. It was identified in medical literature in 2000, and is only known to occur among individuals with kidney disease. There is no known cure or consistently successful treatment available at this time, and many individuals are left severely disabled and dependent on a wheelchair within a few weeks or months of the MRI or MRA.

The October 2007 issue of the American Journal of Dermatology includes a study conducted by researchers at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina. Researchers compared the skin biopsies of several individuals diagnosed with NSF to those of healthy people. The findings suggest that one particular enzyme may explain why those on kidney dialysis face 2% to 4% risk of developing NSF following an MRI with contrast.

Researchers found a significant increase of an enzyme known as transglutaminase-2 (TG2), among those with NSF. The enzyme is involved in blood clotting and wound healing.

The gadolinium contained in MRI contrast agents may activate the enzyme and cause NSF, which explains why the fibrosis can also occur in other organs besides the skin, such as the heart and lungs. Researchers indicate that the use of drugs such as cystemine, which inhibits the activation of TG2, may be a viable strategy for preventing or treating NSF.

Further research is needed, as the new study was limited in size. However, identifying that the enzyme may be involved could be the first step towards finding a cure or treatment. Finding a consistent method of preventing the condition may allow dialysis patients to take full advantage of the benefits provided by a MRI with contrast.

NSF LAWSUITS AND LAWYERS

If you, a friend or family member have been diagnosed with nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD), you may have a claim against the makers of gadolinium based contrast agents. Their failure to properly research their product and warn about the risk of NSF prevented those with kidney problems from avoiding this devastating condition. If you or a loved one feel you may have NSF, call the attorneys at Davis & Crump. at 1-800-277-0300.

 

Contact Us
Davis & Crump is now handling claims for individuals who have been diagnosed with Nephrogenic Systemic Fibrosis (NSF) or Nephronic Fibrosing Dermopathy (NFD). Davis & Crump is experienced in pharmaceutical product liability cases and settlements. If you or a loved one has suffered Nephrogenic Systemic Fibrosis (NSF) or Nephronic Fibrosing Dermopathy (NFD), please contact us at 1-800-277-0300, or send us an email at info@daviscrump.com.